Hepatitis C
AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
The hepatitis C virus (
HCV) NS3/4A protease inhibitor danoprevir (formerly RG7128) plus pegylated interferon/ribavirin produced high cure rates and many patients were eligible for shorter therapy, according to findings presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study
- Details
- Category: HCV Treatment
- Published on Tuesday, 06 December 2011 00:00
Biopharmaceutical company Inhibitex last week announced early safety and efficacy data from a 7-day Phase 1b study evaluating its investigational once-daily hepatitis C virus (HCV) polymerase inhibitor INX-189 plus ribavirin in an interferon-free oral regimen. This study looked at treatment-naive patients with difficult-to-treat HCV genotype 1; the company now plans to test higher doses of INX-189 and combinations with other direct-acting antivirals, and to include people with genotypes 2 or 3.
AASLD 2011: All-Oral Combination of BI 201335, BI 207127 and Ribavirin Shows Good Efficacy at 12 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 01 December 2011 00:00
An interferon-free triple regimen containing the hepatitis C virus (HCV) protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin for 12 weeks suppressed viral load in three-quarters of previously untreated genotype 1 patients, according to findings from the SOUND-C trials presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients
- Details
- Category: Alternative & Complementary Therapy
- Published on Tuesday, 06 December 2011 00:00
Oral silymarin, an extract from the milk thistle plant, was well-tolerated but did not reduce alanine aminotransferase (ALT) or HCV RNA levels or improve quality of life for hepatitis C patients who did not respond to interferon, researchers reported at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco. 
AASLD 2011: Predictors of Response to Boceprevir plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 November 2011 00:00
Low baseline viral load, hepatitis C virus (HCV) subtype 1b, and absent or mild liver damage predicted sustained response to treatment with boceprevir (Victrelis) plus pegylated interferon/ribavirin, researchers report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.
AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
- Details
- Category: HCV Treatment
- Published on Tuesday, 06 December 2011 00:00
Most treatment-naive chronic hepatitis C patients who added the experimental HCV NS5A inhibitor daclatasvir (BMS-790052) to pegylated interferon/ribavirin achieved undetectable viral load at 12 and 24 weeks, according to data presented at the at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) last month in San Francisco.
AASLD 2011: HCV Screening of 1945-1965 Birth Cohort Appears Cost-Effective
- Details
- Category: HCV Testing & Diagnosis
- Published on Tuesday, 22 November 2011 00:00
Screening all people in the U.S. in the 46 to 66 year age group for hepatitis C virus (HCV) infection would identify more than 800,000 additional cases, and offering testing plus treatment if needed would be cost-effective, according to an analysis presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.
Companies to Evaluate Daclatasvir plus TMC435 for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 02 December 2011 00:00
Bristol-Myers Squibb and Tibotec/Janssen announced that they will collaborate on the testing of an all-oral combination regimen for genotype 1 chronic hepatitis C consisting of daclatasvir (BMS-790052) plus TMC435; a clinical trial is expected to start in the first half of 2012.
AASLD 2011: High Sustained Response Rates with PSI-7977 Plus Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Tuesday, 22 November 2011 00:00
Adding the hepatitis C virus (HCV) polymerase inhibitor PSI-7977 to pegylated interferon plus ribavirin produced a 91% cure rate for previously untreated patients with hard-to-treat HCV genotype 1, according to results from the PROTON study presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.
More Articles...
- AASLD 2011: Epidemic of Sexually Transmitted HCV among HIV+ Gay Men in Amsterdam Levels Off
- AASLD 2011: TMC435 + Interferon/Ribavirin Raises Cure Rates for Naive and Experienced Hepatitis C Patients
- AASLD 2011: BI 201335 Performs Well with Standard Therapy
- AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
- AASLD 2011: Do Hepatitis C Patients with Cirrhosis Benefit from Adding Telaprevir?
Web Design and Development by